Insight Molecular Diagnostics Inc. (IMDX) Form 8-K — May 13, 2026
Insight Molecular Diagnostics Inc. (IMDX) reported Q1 2026 revenues of approximately $32,000, all derived from laboratory services performed at its clinical laboratory in Tennessee. The company remains essentially pre-revenue for its primary product, GraftAssureDx, which is currently under FDA review. The company reported a gross profit of $15,000 in Q1 2026, representing a 46.9% gross margin.
Key figures
- Eps Beat
- 0
- Revenue
- 32
- Total Debt
- 51118
- Cash And Equivalents
- 29355
- Pro Forma Fully Weighted Share Count
- 36700
- Weighted Average Shares Outstanding
- 34519
Price after filing
1 day: +25.9%7 days: +21.4%30 days: +6.5%
Close on the filing date to close N calendar days later (from $5.10). Historical, not a forecast.
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.